Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review (vol 13, pg 1571, 2024)

被引：0
|
作者：
Blumenfeld, Andrew M. [1 ,2 ]
Mechtler, Laszlo [3 ]
Cook, Lisa [1 ]
Rhyne, Christopher [4 ]
Jenkins, Brian [5 ]
Hughes, Olivia [6 ]
Dabruzzo, Brett [7 ]
Manack Adams, Aubrey [7 ]
Diamond, Merle [8 ]
机构：
[1] Los Angeles Headache Ctr, Los Angeles, CA 90067 USA
[2] San Diego Headache Ctr, San Diego, CA 92111 USA
[3] Dent Neurol Inst, Buffalo, NY USA
[4] Norton Neurosci Inst, Louisville, KY USA
[5] Neurosci Grp, Neenah, WI USA
[6] ICON Plc, Blue Bell, PA USA
[7] AbbVie, N Chicago, IL USA
[8] Diamond Headache Clin Ltd, Chicago, IL USA
来源：
PAIN AND THERAPY | 2025年 / 14卷 / 01期
关键词：
D O I：
10.1007/s40122-024-00692-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：441 / 444
页数：4
相关论文
共 50 条
  • [21] Real-world evidence of the effectiveness and satisfaction with eptinezumab treatment in patients with chronic migraine
    Argoff, C.
    Khan, F.
    Herzog, S.
    Smith, R.
    Kotak, S.
    Sopina, L.
    Soni-Brahmbhatt, S.
    Kymes, S.
    HEADACHE, 2023, 63 : 160 - 161
  • [22] REAL-WORLD TREATMENT UTILIZATION AND SAFETY OF ONABOTULINUMTOXINA FOR CHRONIC MIGRAINE FROM AN OBSERVATIONAL STUDY IN THE EUROPEAN UNION
    Matharu, M.
    Pascual, J.
    Remahl, I. Nilsson
    Straube, A.
    Lum, A.
    Davar, G.
    Odom, D.
    Bennett, L.
    Proctor, C.
    Gutierrez, L.
    Andrews, E.
    Johannes, C.
    CEPHALALGIA, 2016, 36 : 27 - 27
  • [23] Real-world treatment utilisation and safety of onabotulinumtoxinA for chronic migraine: results from an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Nilsson-Remahl, I.
    Straube, A.
    Lum, A.
    Davar, G.
    Odom, D.
    Bennett, L.
    Proctor, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 115 - 115
  • [24] SYNCHRONIZE: Real-World Retrospective Safety Analysis in Patients with Chronic Migraine Treated with OnabotulinumtoxinA for More Than One Therapeutic Indication
    Blumenfeld, Andrew
    Forde, Grace
    Ifantides, Kim Becker
    Singh, Ritu
    Sommer, Katherine
    Battucci, Simona
    Rhyne, Christopher
    CEPHALALGIA, 2023, 43 (1supp) : 251 - 251
  • [25] Interim analysis of the real-world utilization and safety of onabotulinumtoxina for the prophylactic treatment of chronic migraine in an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Remahl, I. Nilsson
    Straube, A.
    Johannes, C.
    Odom, D.
    Gutierrez, L.
    Andrews, E.
    Lum, A.
    CEPHALALGIA, 2015, 35 : 39 - 39
  • [26] Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
    Fernandez-Bravo-Rodrigo, Jaime
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Flor-Garcia, Amparo
    Barreda-Hernandez, Dolores
    Pascual-Morena, Carlos
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 976
  • [27] Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
    Driessen, Maurice T.
    Cohen, Joshua M.
    Patterson-Lomba, Oscar
    Thompson, Stephen F.
    Seminerio, Michael
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [28] US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review
    Eugeni, Patrick
    Rooney, Megan E.
    Saikali, Nicolas P.
    Niu, Zhongzheng
    Driessen, Maurice T.
    Krasenbaum, Lynda J.
    Carr, Karen
    Seminerio, Michael J.
    Mcvige, Jennifer W.
    ADVANCES IN THERAPY, 2025, 42 (02) : 1207 - 1221
  • [29] Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
    Maurice T. Driessen
    Joshua M. Cohen
    Oscar Patterson-Lomba
    Stephen F. Thompson
    Michael Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
  • [30] Real-world evidence for control of patients with chronic migraine who received calcitonin gene-related peptide monoclonal antibody therapy added to OnabotulinumtoxinA treatment
    Blumenfeld, A. M.
    Frishberg, B. M.
    Schim, J. D.
    Hughes, O.
    Adams, Manack A.
    HEADACHE, 2021, 61 : 106 - 107
12345